The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Recombinant human Dnase I (rhDNase) in patients with lupus nephritis
Abstract
Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies to nucleoprotein antigens, including double-stranded DNA (dsDNA). The deposition of IgG dsDNA immune complexes in glomeruli is thought to be crucial for disease pathogenesis and complement activation. rhDNase catalyzes the hydrolysis of extracellular DNA and has been shown to delay the development of dsDNA antibodies, reduce proteinuria, and delay mortality in a lupus-prone murine model. We conducted a 40 d, phase Ib, randomized, double-masked, placebo-controlled trial to determine the safety and pharmacokinetics of rhDNase, and to measure any changes in markers of disease activity in 17 patients with lupus nephritis. Patients were assigned to receive either: (1) 25 mg/kg rhDNase (n=8); (2) 125 mg/kg rhDNase (n=6); or (3) placebo (n=3) initial single intravenous (IV) dose followed by 10 subcutaneous (SC) doses. Skin biopsies performed on nine patients pre-and post-treatment were studied for immune complex deposition by immunofiuorescence. Serum cytokine levels (sIL2-R, IL-6, IL-10, and TNF-a) were analyzed by ELISA. Cytokine secretion and antibody production were measured by ELISPOT analysis and ELISA. Serum hydrolytic activity of rhDNase was achieved after IV administration at 25 and 125 mg/kg, but not after SC administration at either dose. A t 12 of 3–4 h was estimated from serum concentration profiles following IV administration. Serum dsDNA antibodies were unchanged (mean values: 33 IU/mL vs 39 IU/mL [pre-and post-treatment] for the 25 mg/kg group, and 74 IU/mL vs 74 IU/mL for the 125 mg/kg group, and 14 IU/mL vs 20 IU/mL for the placebo group). Complement levels (C3 and C4) and circulating immune complexes did not change appreciably during the treatment period for any of the groups. Serum cytokine profiles by ELISA revealed no changes in sIL-2 receptor, IL-6, IL-10, or TNF-a. There was no change in the number of cells secreting either Th1 or Th2 specific cytokines, nor in the number of cells secreting dsDNA antibodies. Neutralizing antibodies to rhDNase were not detected in serum at any time during the study. Immune complex deposition was unchanged in pre-and post-treatment in skin biopsies in both dose groups. rhDnase was well tolerated without significant adverse events following administration, and treatment was not associated with the development of neutralizing antibodies to rhDNase. Serum rhDNase concentrations capable of hydrolytic activity of rhDNase were achieved for a few hours following IV, but not SC administration. Serum markers of disease activity were unchanged during the study period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
Cited by
An emerging role for neutrophil extracellular traps in noninfectious disease
Jorch, S. K., & Kubes, P. (2017) · Nature Medicine · doi:10.1038/nm.4294 · Cited by 1,244
Tohme, S., Yazdani, H. O., Al-Khafaji, A. B., Chidi, A. P., Loughran, P., Mowen, K., Wang, Y., Simmons, R. L., Huang, H., & Tsung, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1591 · Cited by 694
Leffler, J., Martin, M., Gullstrand, B., Tydén, H., Lood, C., Truedsson, L., Bengtsson, A. A., & Blom, A. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102404 · Cited by 516
Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases
Wigerblad, G., & Kaplan, M. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00787-0 · Cited by 502
The role of neutrophils and NETosis in autoimmune and renal diseases
Gupta, S., & Kaplan, M. J. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.71 · Cited by 433
Metadata
- Authors
- Davis, J. C., Manzi, S., Yarboro, C., Rairie, J., Mcinnes, I., Averthelyi, D., Sinicropi, D., Hale, V. G., Balow, J., Austin, H., Boumpas, D. T., & Klippel, J. H.
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 1999-01
- Volume
- 8
- Issue
- 1
- Pages
- 68-76
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2037926559
- Cited by
- 236
- References
- 1
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. https://app.cochat.ai/papers/10.1191/096120399678847380
- The paper
- Davis, J. C., Manzi, S., Yarboro, C., Rairie, J., Mcinnes, I., Averthelyi, D., Sinicropi, D., Hale, V. G., Balow, J., Austin, H., Boumpas, D. T., & Klippel, J. H. (1999). Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. https://doi.org/10.1191/096120399678847380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.